It is well acknowledged that a different approach is needed to evaluate new Orphan Medicines compared to standard medicines and vaccines, due to the small population numbers that are impacted by rare diseases.
With limited published evidence available, how can we adopt an enhanced approach to reviewing all the available information on new rare disease medicines in order to support clinical decision making?
This webinar will bring together experts and methodologists experienced in successfully navigating the underlying issues. They will propose solutions for developing effective guidelines for the evaluation of evidence to support clinical decision making for people living with a rare or complex condition.
It is well acknowledged that a different approach is needed to evaluate new Orphan Medicines compared to standard medicines and vaccines, due to the small population numbers that are impacted by rare diseases.